Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours.

Authors :: Boss, D. S.
Schwartz, G. K.
Middleton, M. R.
Amakye, D. D.
Swaisland, H.
Midgley, R. S.
Ranson, M.
Danson, S.
Calvert, H.
Plummer, R.
Morris, C.
Carvajal, R. D.
Chirieac, L. R.
Schellens, J. H. M.
Shapiro, G. I.
Source :: Annals of Oncology. Apr2010, Vol. 21 Issue 4, p884-894. 11p. 4 Charts, 3 Graphs.
Publication Year :: 2010
Abstract: Background: AZD5438 is an orally bioavailable inhibitor of cyclin E-cdk2, cyclin A-cdk2 and cyclin B-cdk1 complexes. Three phase I studies assessed the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5438 when administered in different dosing schedules. [ABSTRACT FROM PUBLISHER]

Subjects :: *PHARMACOKINETICS
*PHARMACODYNAMICS
*CYCLINS
*DRUG dosage
*PROTEIN kinases

Full Text Access

Tools